GSK 3532795

Drug Profile

GSK 3532795

Alternative Names: BMS 955176; GSK3532795; HIV maturation inhibitor

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer GlaxoSmithKline; ViiV Healthcare
  • Class Antivirals; Small molecules
  • Mechanism of Action HIV replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II HIV-1 infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in HIV-1-infections(In volunteers) in United Kingdom (PO, Suspension)
  • 25 Sep 2017 Bristol-Myers Squibb terminates a phase II trial due to GI intolerability in HIV-1 infections (Combination therapy, Treatment-experienced) in USA, Puerto Rico, Australia, Chile, Mexico, Taiwan, Argentina, Canada, Colombia, Peru, Russia, South Africa, and Thailand (PO) (NCT02386098)
  • 21 Aug 2017 Bristol-Myers Squibb terminates phase II trial in HIV-1 infections (Combination therapy, Treatment-naive) in USA, Argentina, Canada, Chile, Mexico, Puerto Rico, Poland, United Kingdom, France, Germany, Spain, Italy, South Africa and Thailand (NCT02415595)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top